SecBot SecBot
Biotech Drug Report Generated Oct 31, 2026

Aprovel

SNY·Sanofi
NEUTRAL
Drug Impact Rating3/10
Trial phase
Approved
Time to market
Already approved and marketed since 1997. Widely available as a generic.
Why 3/10
Aprovel is an already-approved, off-patent drug with no pending regulatory decision or pivotal readout. It represents a very small portion of Sanofi's diversified ~$47B revenue base. Per the rubric, an approved drug with no upcoming binary catalyst scores 3-5, and this one is at the low end given its generic competition and minimal contribution to Sanofi's overall value.
Actionable Insight NEUTRAL

Aprovel/irbesartan has no scheduled PDUFA dates, pivotal readouts, or regulatory catalysts. Sanofi's stock is driven by its broader pipeline (Dupixent, vaccines, rare disease assets) and overall earnings, not this off-patent hypertension drug. Investors should watch Sanofi's pipeline programs and quarterly results rather than this mature product.

Price Chart

Loading chart...

Executive Summary

Aprovel is the brand name for irbesartan, an angiotensin II receptor blocker (ARB) used to treat hypertension and diabetic kidney disease. Developed by Sanofi, it was first approved by the FDA in 1997 (marketed as Avapro in the US) and is now off-patent with widespread generic competition. The drug generated roughly $494 million in global sales for Sanofi in 2025, a small fraction of the company's ~$47 billion annual revenue. There are no upcoming binary catalysts for this mature product, and it is not a meaningful driver of Sanofi's share price.

How It Works

Aprovel (irbesartan) is an angiotensin II receptor blocker (ARB). It works by blocking the action of angiotensin II, a hormone that causes blood vessels to narrow. By blocking this hormone, the drug helps blood vessels relax and widen, which lowers blood pressure and improves blood flow. It is taken as a once-daily oral tablet.

Trial Status

Irbesartan was approved by the FDA on September 30, 1997 (brand name Avapro) and by the European Medicines Agency in 1997 (brand name Aprovel). It is a mature, off-patent drug with established generic competition. A supplemental new drug application (sNDA) for a labeling update was approved by the FDA on August 1, 2025, adding updated safety information. The drug continues to be marketed but no new pivotal trials are underway.

The Two-Sided Case

▲ Bull Case3
Irbesartan remains a widely prescribed antihypertensive with steady demand, generating roughly $494 million in 2025 global sales for Sanofi, up 12.7% year-over-year.
The drug has a well-established safety profile and is included in major hypertension treatment guidelines, ensuring continued prescription volume.
Sanofi's broad portfolio means the drug contributes predictable, if modest, cash flow with no further R&D investment required.
▼ Bear Case4
The drug is off-patent and faces extensive generic competition from multiple manufacturers (Macleods, Hisun, and others), which severely limits pricing power and margins.
At roughly $494 million in annual sales, irbesartan represents less than 1% of Sanofi's total revenue, making it immaterial to the company's investment thesis.
There are no upcoming catalysts for this drug that could move Sanofi's share price, as it is a mature product with no pending regulatory actions or new indications.
Multiple large institutional holders trimmed or exited Sanofi positions in Q2 2026, and several analysts downgraded the stock in late 2025/early 2026.

Upcoming Catalysts

  • No upcoming binary catalysts for this drug. It is a mature, off-patent product with no scheduled PDUFA dates, pivotal readouts, or regulatory decisions.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Sanofi 6-K SNY ·Originating report

Sources · 9

Hover a chip for the title
1 en.wikipedia.org2 ema.europa.eu3 drugs.com4 accessdata.fda.gov5 pharmacompass.com6 bioplayground.com7 drugpatentwatch.com8 biopharmawatch.com9 stockanalysis.com